Grant: Operating Grant

Prostate cancer is the most frequently diagnosed malignancy in Canadian males and the third leading cause of cancerrelated death in men in most Western industrialized countries. Estimations assume that approximately 660,000 men worldwide will be diagnosed with this form of cancer and 250,000 men will die from it in 2010. We discovered that a series of natural or synthetic compounds, which modulate gene expression through activation of a protein named FXR, are efficient blockers of the growth of common prostate cancer cell lines. In this application, we propose to determine the therapeutic interest of these molecules in vitro and in animals models.